{"id":"NCT00105989","sponsor":"Eli Lilly and Company","briefTitle":"Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder","officialTitle":"Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-03","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2005-03-21","resultsPosted":"2009-07-17","lastUpdate":"2009-07-28"},"enrollment":514,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.","primaryOutcome":{"measure":"Percentage of Participants With Depressive Recurrence After Time (t) in Days","timeFrame":"Every Visit from Week 34 up to Week 86 (Maintenance Phase)","effectByArm":[{"arm":"Duloxetine","deltaMin":0.68,"sd":null},{"arm":"Placebo","deltaMin":2.11,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":34,"countries":["United States","France","Germany","Italy","Russia","Sweden"]},"refs":{"pmids":["19552867"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5},"commonTop":["Headache","Hyperhidrosis","Nasopharyngitis","Back pain","Dry mouth"]}}